0001626199-23-000147.txt : 20231227
0001626199-23-000147.hdr.sgml : 20231227
20231227210756
ACCESSION NUMBER: 0001626199-23-000147
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20231222
FILED AS OF DATE: 20231227
DATE AS OF CHANGE: 20231227
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: GOLD MITCHELL
CENTRAL INDEX KEY: 0001242882
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-37449
FILM NUMBER: 231519225
MAIL ADDRESS:
STREET 1: ALPINE IMMUNE SCIENCES, INC.
STREET 2: 188 EAST BLAINE STREET, SUITE 200
CITY: SEATTLE
STATE: WA
ZIP: 98102
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: ALPINE IMMUNE SCIENCES, INC.
CENTRAL INDEX KEY: 0001626199
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 208969493
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 188 EAST BLAINE ST., SUITE 200
CITY: SEATTLE
STATE: WA
ZIP: 98102
BUSINESS PHONE: 206-788-4545
MAIL ADDRESS:
STREET 1: 188 EAST BLAINE ST., SUITE 200
CITY: SEATTLE
STATE: WA
ZIP: 98102
FORMER COMPANY:
FORMER CONFORMED NAME: Nivalis Therapeutics, Inc.
DATE OF NAME CHANGE: 20150211
FORMER COMPANY:
FORMER CONFORMED NAME: N30 Pharmaceuticals, Inc.
DATE OF NAME CHANGE: 20141121
4
1
wk-form4_1703729261.xml
FORM 4
X0508
4
2023-12-22
0
0001626199
ALPINE IMMUNE SCIENCES, INC.
ALPN
0001242882
GOLD MITCHELL
C/O ALPINE IMMUNE SCIENCES, INC.
188 EAST BLAINE STREET, SUITE 200
SEATTLE
WA
98102
1
1
0
0
Executive Chairman and CEO
1
Common Stock
2023-12-22
4
M
0
37825
0.45
A
37825
D
Common Stock
2023-12-22
4
S
0
37825
20.4255
D
0
D
Common Stock
2023-12-26
4
M
0
2402
0.45
A
2402
D
Common Stock
2023-12-26
4
M
0
22084
0.65
A
24486
D
Common Stock
2023-12-26
4
S
0
24486
20.2245
D
0
D
Common Stock
2023-12-27
4
M
0
29573
0.65
A
29573
D
Common Stock
2023-12-27
4
S
0
29573
20.0425
D
0
D
Common Stock
2600980
I
Alpine ImmunoSciences, L.P.
Stock Option (Right to buy)
0.45
2023-12-22
4
M
0
37825
0
D
2025-12-15
Common Stock
37825
2402
D
Stock Option (Right to buy)
0.45
2023-12-26
4
M
0
2402
0
D
2025-12-15
Common Stock
2402
0
D
Stock Option (Right to buy)
0.65
2023-12-26
4
M
0
22084
0
D
2027-03-13
Common Stock
22084
278540
D
Stock Option (Right to buy)
0.65
2023-12-27
4
M
0
29573
0
D
2027-03-13
Common Stock
29573
248967
D
The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting persons on March 30, 2023.
This transaction was executed in multiple trades at prices ranging from $20.00 to $20.87. The price reported above reflects the weighted average sales price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
This transaction was executed in multiple trades at prices ranging from $20.00 to $20.51. The price reported above reflects the weighted average sales price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
This transaction was executed in multiple trades at prices ranging from $20.00 to $20.37. The price reported above reflects the weighted average sales price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
Alpine BioVentures GP, LLC is the general partner of Alpine ImmunoSciences, L.P. Dr. Gold is a Managing Partner of Alpine BioVentures GP, LLC. Dr. Gold is also a limited partner of Alpine ImmunoSciences, L.P. By virtue of such relationships, Dr. Gold may be deemed to have voting and investment power with respect to the shares held by Alpine ImmunoSciences, L.P. and as a result may be deemed to have beneficial ownership of such shares.
The Reporting Person disclaims beneficial ownership of the shares of common stock reported herein except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of such shares for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.
100% of the shares underlying the option were fully vested as of January 16, 2019.
100% of the shares underlying the option were fully vested as of January 20, 2021.
/s/ Mitchell Gold
2023-12-27